<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470210</url>
  </required_header>
  <id_info>
    <org_study_id>MORE</org_study_id>
    <secondary_id>2006-005554-74</secondary_id>
    <nct_id>NCT00470210</nct_id>
  </id_info>
  <brief_title>Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens</brief_title>
  <official_title>Efficacy and Safety of High-dose Ribavirin (1600 mg/d) Boosted With Epoetin β (450 IU/kg/wk) in HIV/HCV Coinfected Patients Not Responding to Previous Treatment Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will assess the sustained virologic response to treatment with peginterferon
      alfa-2a combined with high-dose ribavirin in human immunodeficiency virus (HIV)-infected
      patients with hepatitis C virus (HCV) genotype 1 or 4 coinfection and persistent transaminase
      elevations. These patients will have been nonresponders to previous regimens with
      peginterferon alfa and ribavirin therapy at a dosage of 800-1200 mg/d.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose in treating chronic HCV infection in HIV-coinfected individuals is to clear
      HCV-RNA antibodies and cure the infection. Studies have shown that high doses of ribavirin
      are associated with higher response rates than those achieved with ribavirin at dosages of
      800-1200 mg/d.

      The main aim of this trial is to assess the sustained virologic response to treatment with
      peginterferon alfa-2a plus high-dose ribavirin in HIV-infected patients coinfected with HCV
      genotypes 1 or 4 who have had persistent transaminase elevations and lack of response to
      previous treatment with peginterferon alfa and ribavirin at dosages of 800-1200 mg/d.

      The second aim will be to measure changes in serum HCV-RNA titers and the percentage of
      patients achieving serum viral loads of &lt; 50 IU/mL during treatment. Finally, we also intend
      to evaluate the safety of this treatment regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of sustained virologic response measured as serum HCV-RNA loads of &lt; 50 IU/mL</measure>
    <time_frame>24 weeks after finishing treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum HCV-RNA titers</measure>
    <time_frame>between baseline and 4, 8, 12, 24, and 48 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with serum HCV-RNA loads of &lt; 50 IU/mL</measure>
    <time_frame>at weeks 4, 8, 12, 24, and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week Ribavirin (Copegus®) 1600 mg/day Epoetin β (450 UI/kg/week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week</intervention_name>
    <description>Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (Copegus®) 1600 mg/day</intervention_name>
    <description>Ribavirin (Copegus®) 1600 mg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin β (450 UI/kg/week)</intervention_name>
    <description>Epoetin β (450 UI/kg/week)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected patients coinfected with HCV genotypes 1 or 4

          -  Persistent transaminase elevation

          -  Nonresponders to previous treatment with peginterferon alfa plus ribavirin at a dosage
             of 800-1200 mg/d.

        Exclusion Criteria:

          -  Patients who abandoned treatment with peginterferon plus ribavirin before 12 weeks

          -  Patients with Child-Pugh B or C cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonaventura Clotet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Tural, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2007</study_first_submitted>
  <study_first_submitted_qc>May 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <last_update_submitted>April 15, 2010</last_update_submitted>
  <last_update_submitted_qc>April 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>LLuita Sida Foundation</name_title>
    <organization>LLuita Sida Foundation</organization>
  </responsible_party>
  <keyword>Ribavirin</keyword>
  <keyword>non-responders</keyword>
  <keyword>HCV co-infected patients</keyword>
  <keyword>sustained virological response</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

